Inhaled Antibiotics Market 2024 - By Size, Share Analysis, Future Insights, Current Trends And Global Growth Outlook By 2033

 

Overview and Scope

Inhaled antibiotics refer to drugs that act as medication for respiratory-related problems. Inhaled antibiotics have enhanced survival and have been used to improve lung function, delay deterioration in lung function, extend time between exacerbations, and improve quality of life.

 

Sizing and Forecast

The inhaled antibiotics market size has grown strongly in recent years. It will grow from $1.46 billion in 2023 to $1.58 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%.  The  growth in the historic period can be attributed to regulatory support and approvals, shift from systemic to targeted delivery, rise in antibiotic resistance, increase in respiratory infections..

 

The inhaled antibiotics market size is expected to see strong growth in the next few years. It will grow to $2.18 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%.  The growth in the forecast period can be attributed to growing investments in research and development, expansion of clinical applications, increasing focus on personalized medicine, advancements in drug formulations, continued antibiotic resistance concerns.. Major trends in the forecast period include continued innovation in formulations, patient-centric approach, increased research in respiratory health, shift towards targeted therapies, advancements in drug delivery systems..

 

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report

 

Segmentation & Regional Insights

The inhaled antibiotics market covered in this report is segmented –

1) By Product Type: Aerosol or Metered Dose Inhaler, Dry Powder Formulation, Spray, Other Types

2) By Application: Pneumonia, Asthma, Bronchitis, Other Applications

3) By End-User: Hospitals, Other End Users

 

Top Major Players

Gilead Sciences Inc.

Lupin Limited

Insmed Inc.

Savara Inc.

Joincare Pharmaceutical Group Industry Co. Ltd.

 

North America was the largest region in the inhaled antibiotics market share in 2023. The regions covered in the inhaled antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

 

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8738&type=smp

 

Major Driver Impacting Market Growth

The increasing incidence of respiratory diseases is expected to propel the growth of the inhaled antibiotics market going forward. Respiratory disease is a disease that damages the lungs and airways and impairs breathing in people. Inhaled antibiotics enhance lung function, prevent lung function decline, extend the period between exacerbations, and enhance the quality of life in cystic fibrosis patients. For instance, in June 2023, according to reports published by the Australian Institute of Health and Welfare, an Australia-based national agency, there was a rise in respiratory disease-related deaths in 2021 i.e., 46,551 in Australia. Furthermore, in September 2022, according to the data published by The Lancet, a UK-based book and periodic data publishing organization, 11,255 new cases of respiratory syncytial virus (RSV) were recorded in the 2021 summer, which is 9.50% more. Therefore, an increasing incidence of respiratory diseases drives the inhaled antibiotics market .

Key Industry Players

Major companies operating in the inhaled antibiotics market report are Gilead Sciences Inc., Lupin Limited, Insmed Inc., Savara Inc., Joincare Pharmaceutical Group Industry Co. Ltd., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., Raptor Pharmaceutical Corporation, Altan Pharma Limited, Cipla Limited, Maya Biotech Pvt. Ltd., Medisol Lifescience Pvt. Ltd., Nivon Specialties, Sentiss Pharma Pvt. Ltd., Ultratech India Limited, Midas Care Pharmaceuticals Pvt. Ltd., Precept Pharma Ltd., Luckys Pharma, Novartis AG, Bayer AG, Pfizer Inc., Grifols SA, Vertex Pharmaceuticals Inc., Aridis Pharmaceuticals, Bayer HealthCare, Nektar Therapeutics, Parion Sciences Inc., Zambon Group, Transave Inc., Alitair Pharmaceuticals, Synspira Therapeutics Inc., AIT Therapeutics Inc., Polyphor AG, Oppilan Pharma Ltd., OptiNose Inc.

 

The inhaled antibiotics market report table of contents includes:

1. Executive Summary

2. Inhaled Antibiotics Market Characteristics

3. Inhaled Antibiotics Market Trends And Strategies

4. Inhaled Antibiotics Market - Macro Economic Scenario

5. Global Inhaled Antibiotics Market Size and Growth

............................

31. Global Inhaled Antibiotics Market Competitive Benchmarking

32. Global Inhaled Antibiotics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Inhaled Antibiotics Market

34. Inhaled Antibiotics Market Future Outlook and Potential Analysis

35. Appendix

 

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info 

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model